0001493152-23-010223 | 10-K | XBRL Viewer

Print Document View Excel Document

SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 2,442	$ 13,493
Total marketable securities	5,760	1,999
Total cash and cash equivalents and marketable securities	8,202	15,492
Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Total marketable securities	1,999	1,999
US Treasury Securities [Member]
Cash and Cash Equivalents [Line Items]
Total marketable securities	3,761
Cash [Member]
Cash and Cash Equivalents [Line Items]
Total cash and cash equivalents	1,195	13,493
US Treasury Securities [Member]
Cash and Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 1,247

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 4 - FAIR VALUE MEASUREMENTS

Fair value measurement

The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of December 31, 2022 and 2021:

	As of December 31, 2022
	Total		Level 1		Level 2		Level 3

Cash equivalents:
U.S. treasury securities	$	1,247	$	1,247	$	-	$	-

Marketable securities:
U.S. treasury securities	$	3,761	$	3,761	$	-	$	-
Money market mutual funds		1,999		1,999		-		-
	$	5,760	$	5,760	$	-	$	-

	As of December 31, 2021
	Total		Level 1		Level 2		Level 3

Cash equivalents:
Money market funds	$	- (*)	$	- (*)	$	-	$	-

Marketable securities:
Money market mutual funds	$	1,999	$	1,999	$	-	$	-

(*)

Reclassified

The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s securities and money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of December 31, 2022 and 2021.

SCHEDULE OF STATUTORY CORPORATE TAX RATE AND EFFECTIVE INCOME TAX RATE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Net loss	$ (13,168)	$ (11,313)
Income Tax under statutory tax rate	2,922	2,513
Change in valuation allowance	(2,922)	(2,513)
Actual provision for income taxes
Minimum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Statutory tax rate	21.00%	21.00%
Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Statutory tax rate	23.00%	23.00%
ISRAEL
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Net loss	$ 8,065	$ 6,853
UNITED STATES
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Net loss	$ 5,103	$ 4,460

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2022	Mar. 30, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-19871
Entity Registrant Name	MICROBOT MEDICAL INC.
Entity Central Index Key	0000883975
Entity Tax Identification Number	94-3078125
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	25 Recreation Park Drive
Entity Address, Address Line Two	Unit 108
Entity Address, City or Town	Hingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02043
City Area Code	(781)
Local Phone Number	875-3605
Title of 12(b) Security	Common Stock, Par value $0.01
Trading Symbol	MBOT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 34,521,094
Entity Common Stock, Shares Outstanding		8,130,628
ICFR Auditor Attestation Flag	false
Auditor Firm ID	1197
Auditor Name	Brightman Almagor Zohar & Co
Auditor Location	Tel Aviv, Israel

PROPERTY AND EQUIPMENT, NET

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT, NET

NOTE 7 - PROPERTY AND EQUIPMENT, NET

SUMMARY OF PROPERTY AND EQUIPMENT, NET

	As of December 31,
	2022		2021

Cost:
Research equipment and software	$	71	$	68
Leasehold improvement		229		229
Furniture and office equipment		308		236
		608		533
Accumulated Depreciation:
Research equipment and software		63		54
Leasehold improvement		135		89
Furniture and office equipment		189		146
		387		289
	$	221	$	244

LEASES (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
LEASES (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2022	Nov. 30, 2019
Leases
Short-term lease term		5 years
Lease payment	$ 16
Issued bank guarantee	$ 54

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 9 - COMMITMENTS AND CONTINGENCIES

Government Grants:

Microbot Israel has received grants from the Israeli Innovation Authority (“IIA”) for participation in research and development since 2013 through December 31, 2022 totaling approximately $1,500.

In addition, as a result of the agreement with CardioSert Ltd. (“CardioSert”) on January 4, 2018, Microbot Israel took over the liability to repay CardioSert’s IIA grants in the aggregate amount of approximately $530.

In addition, as a result of the agreement with Nitiloop, on October 6, 2022, Microbot Israel took over the liability to repay Nitiloop’s IIA grants in the aggregate amount of approximately $925.

In relation to the IIA grants described above, the Company is obligated to pay royalties amounting to 3.0%-3.5% of its future sales of the products relating to such grants.

The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of Libor per annum.

The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis.

TRDF Agreement:

Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license (as amended, the License Agreement”). As partial consideration for the license, Microbot Israel shall pay TRDF royalties on net sales (between 1.5%-3.0%) and on sublicense income as detailed in the agreement.

Pursuant to the License Agreement, both parties agreed to extend the next development milestone for the Company’s Self Cleaning Shunt (SCS) project, which includes the First In Human milestone, until December 2024, and to continue to maintain the TipCat assets, which are still in a discovery phase, until December 2023. The Company in October 2022 suspended the SCS project while it evaluates alternatives for the SCS assets (mainly related patents), which may include seeking buyers for the assets, entering into joint ventures or licensing arrangements, spinning off the assets into a new operating company or discontinuing the project altogether. The Company has certain obligations to seek to develop and commercialize the SCS and the TipCat assets under the License Agreement. At the time of filing of this Annually Report on Form 10-K, the Company has been in discussions with TRDF with respect to the suspension of the SCS project and the status of the TipCat assets, and the Company expects that if it is unsuccessful in entering into alternative arrangements for such assets, the Company will return the licensed assets to TRDF.

Agreement with CardioSert Ltd.:

On January 4, 2018, Microbot Israel entered into an agreement with CardioSert to acquire certain patent-protected technology owned by CardioSert (the “Technology”). Pursuant to the Agreement, Microbot Israel made an initial payment of $50 to CardioSert and had 90-days to elect to complete the acquisition. At the end of the 90-day period, at Microbot Israel’s sole option, CardioSert shall assign and transfer the Technology to Microbot Israel and Microbot Israel shall pay to CardioSert additional amounts and securities as determined in the agreement.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

On May 25, 2018, Microbot Israel, delivered an Exercise Notice to CardioSert Ltd., notifying it that Microbot Israel elected to exercise the option to acquire the Technology owned by CardioSert and therefore made an additional cash payment of $250 and 6,738 shares of common stock estimated at $74.

The agreement may be terminated by Microbot Israel at any time for convenience upon 90-days’ notice. The agreement may be terminated by CardioSert in case the first commercial sale does not occur by the third anniversary of the date of signing of the agreement except if Microbot Israel. has invested more than $2,000 in certain development stages, or the first commercial sale does not occur within 50 months. As of December 31, 2022, the 50 months period has expired and CardioSert can buy-back the Technology at any time. As of the report date, CardioSert has not purchased back the Technology.

In each of the above termination events, or in case of breach by Microbot Israel, CardioSert shall have the right to buy back the Technology from Microbot Israel for $1.00, upon 60 days prior written notice, but only 1 year after such termination. Additionally, the agreement may be terminated by either party upon breach of the other (subject to cure). CardioSert agreed to assist Microbot Israel in the development of the Technology for a minimum of one year, for a monthly consultation fee of NIS40 (or approximately US$11.37, based on an exchange rate of NIS 3.519 to the dollar) covering up to 60 consulting hours per month.

ATM Agreement:

On June 10, 2021, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co. LLC (“Wainwright”), as sales agent, in connection with an “at the market offering” under which the Company may offer and sell, from time to time in its sole discretion, shares of its Common Stock having an aggregate offering price of up to $10,000 at market prices or as otherwise agreed with Wainwright. Any shares sold under the ATM Agreement from time to time will be offered and sold pursuant to the Company’s Registration Statement on Form S-3, which was initially filed on November 25, 2020 and which was declared effective by the SEC on December 4, 2020, and the related prospectus as supplemented by a prospectus supplement that the Company filed on June 10, 2021 (the “June 2021 Prospectus”). To date, we have not sold any shares of Common Stock pursuant to the ATM Agreement, and as of October 13, 2022, the Company suspended the ATM Agreement, which remains in full force and effect, and terminated the June 2021 Prospectus.

Acquisition of Nitiloop’s Assets

On October 6, 2022, Microbot Israel purchased substantially all of the assets, including intellectual property, devices, components and product related materials (the “Assets”), of Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”). The Assets include intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter (the “Technology”) and the products or potential products incorporating the Technology owned by Nitiloop and designated by Nitiloop as “NovaCross”, “NovaCross Xtreme” and “NovaCross BTK” and any enhancements, modifications and improvements thereof (“Devices”). Microbot Israel did not assume any material liabilities of Nitiloop other than obligations Nitiloop has to the IIA and relating to certain renewal/maintenance fees for a European patent application.

In consideration for the acquisition of the Assets, Microbot Israel shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed $8,000, as follows:

	●	Royalties at a rate of 3% of net revenue generated as a result of sales, license or other exploitation of the Devices; and
	●	Royalties at a rate of 1.5% of net revenue generated from the sale, license or other exploitation of commercialization of the technology as part of an integrated product.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is accounted for as business combination or an acquisition of assets. Based on the Company’s analysis, the Company concluded that the acquisition of the assets does not meet the definition of a business for the purpose of applying SEC Rules (S-X Rules of 3-05, 8-04 and 11-01).

Litigation:

Litigation Resulting from 2017 Financing

The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., Plaintiffs, against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020). The complaint alleges, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017 equity financing (the “Financing”), of which the Plaintiffs participated, and fraudulently induced Plaintiffs into signing the SPA. The complaint seeks rescission of the SPA and return of the Plaintiffs’ $6,750 purchase price with respect to the Financing. The Company is currently in the discovery phase. Management is unable to assess the likelihood that the Company will succeed at trial with respect to the SPA or the Financing, having previously lost another lawsuit with respect to the Financing.

Alliance Litigation

On April 28, 2019, the Company brought an action against Alliance Investment Management, Ltd. (“Alliance”), later amended to include Joseph Mona (“Mona”) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934, 15 U.S.C. 78p(b), to compel Alliance and Mona to disgorge short swing profits realized from purchases and sales of the Company’s securities within a period of less than six months. The case is Microbot Medical Inc. v. Alliance Investment Management, Ltd., No. 19-cv-3782-GBD (SDNY). The amount of profits was estimated in the complaint to be approximately $468.

On October 28, 2019, Alliance filed a motion for summary judgment requesting that the Court dismiss the claims against Alliance. On February 4, 2020, Mona answered the 16(b) claim the Company asserted against him by claiming various equitable defenses and filed a counterclaim against the Company under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming a net loss on trading the Company’s stock of approximately $151.

On September 17, 2020, the Court issued a Memorandum Decision & Order that, among other things, granted Alliance’s summary judgment motion.

On March 30, 2021, the Court issued an Order; and on March 31, 2021, the Clerk entered judgment against Mona and in favor of the Company in the amount of approximately $485. On April 27, 2021, Mona filed an appeal of the Court’s judgment, which is pending before the U.S. Court of Appeals for the Second Circuit.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

In June 2021, the Magistrate issued an order permitting Mona to file an Amended Counterclaim Complaint, and rejected the Company’s request to execute on the judgment. The Company filed a response to Mona’s amended counterclaim in July 2021, and in February 2023 filed a motion for summary judgment on Mona’s fraud claim on the basis of inability to demonstrate reliance or loss causation. The motion is scheduled to be fully briefed and submitted on May 1, 2023.

TAXES ON INCOME (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES


	For the Years Ended December 31,
	2022			2021

Net operating loss carryforwards	$	113,393		$	109,483
Operation lease liabilities		105			156
Accrued vacation pay		71			45
Total deferred tax assets		113,569			110,684
Less: valuation allowance		(113,455	)		(110,536	)
Net deferred tax assets		114			148

Operating leases, right-of-use assets		(114	)		(148	)
Total deferred tax liabilities		(114	)		(148	)
Total net deferred tax assets	$	-		$	-

SCHEDULE OF STATUTORY CORPORATE TAX RATE AND EFFECTIVE INCOME TAX RATE

The following is a reconciliation of the taxes on income assuming that all income is taxed at the ordinary statutory corporate tax rate in Israel and the effective income tax rate:

	For the Years Ended December 31,
	2022			2021

Net loss in Israel	$	8,065		$	6,853
Net loss in U.S.	$	5,103		$	4,460
Statutory tax rate		21%-23%			21%-23%
Income Tax under statutory tax rate		2,922			2,513
Change in valuation allowance		(2,922	)		(2,513	)
Actual provision for income tax	$	-		$	-

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies applied in the preparation of the financial statements are as follows:

Basis of presentation:

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Financial statement in U.S. dollars:

The functional currency of the Company is the U.S. dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.

Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of Accounting Standards Codification (“ASC”) 830-10, “Foreign Currency Translation”.

All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.

Principles of consolidation:

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions have been eliminated in consolidation.

Cash and cash equivalents:

Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of three months or less at the date of purchase.

Restricted cash:

Restricted cash as of December 31, 2022 and 2021 included an $77 and $87, respectively, collateral account for the Company’s leases agreements and credit line from the bank.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Fair value of financial instruments:

The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments.

The Company measures the fair value of certain of its financial instruments (such as marketable securities) on a recurring basis. The method of determining the fair value of marketable securities is discussed in Note 4.

A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Concentrations of credit risk

Financial instruments which potentially subject the Company to credit risk consist primarily of cash and cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.

Property and equipment:

Property and equipment are presented at cost less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, at the following annual rates:

	%

Research equipment and software		25-33
Furniture and office equipment		7
Leasehold improvements		Over the lease period

Liabilities due to termination of employment agreements:

Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (“Article 14”). According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company’s balance sheets.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Basic and diluted net loss per share:

Basic net loss per share is calculated by dividing net loss attributable to common stock shareholders by the weighted average number of shares of common stock outstanding during the year without consideration of potentially dilutive securities. Diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method.

All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the years ended December 31, 2022 and December 31, 2021, since all such securities have an anti-dilutive effect.

Research and development expenses

Research and development expenses are charged to the statement of comprehensive loss as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses.

Share-based compensation:

The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values.

ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date.

The Company accounts for shares and warrant grants issued to non-employees using the guidance of ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” which expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services.

The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector for equity awards granted prior to the Merger and on the Company’s trading share price for equity awards granted subsequent to the Merger. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term.

The expected stock option term is calculated for stock options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Income Taxes:

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2022, and 2021, the Company had a full valuation allowance against deferred tax assets.

Marketable securities:

The Company invests in various debt securities and an equity security. Debt securities consist of U.S. treasury securities. Equity security consist of a mutual fund. The Company records these investments in the consolidated balance sheet at fair value. For all of the Company’s debt securities, the Company elected the fair value option and thus all unrealized gains or losses for these securities are included in financing income, net. Unrealized gains or losses for the equity security are included in financing income, net. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

Leases

The Company implements ASU 2016-02, Leases (“Topic 842”). This ASU requires entities that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months.

Arrangements that are determined to be leases at inception are recognized as long-term right-of-use assets (“ROU”) and lease liabilities in the balance sheet at lease commencement. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future fixed lease payments over the lease term at commencement date. As most of the Company’s leases do not provide an implicit rate, the Company applies its incremental borrowing rate based on the economic environment at commencement date in determining the present value of future payments. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases or payments are recognized on a straight-line basis over the lease term.

The Company determines if an arrangement is a lease at inception. Operating lease assets are presented as operating lease ROU assets, and corresponding as lease liabilities (current portion), and as operating long-term lease liabilities, on the Company’s consolidated balance sheets.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the remaining lease payments over the lease term at commencement date. The Company’s leases do not provide an implicit interest rate. The Company calculates the incremental borrowing rate to reflect the interest rate that it would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term and considers the Company’s historical borrowing activities and market data in this determination. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

The Company has lease agreements with lease and non-lease components, which it accounts for as a single lease component. The Company has elected not to recognize ROU assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on the Company’s ROU assets and lease liabilities was not material. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any related party leases and its sublease transactions are de minimis.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Contingencies

Management records and discloses legal contingencies in accordance with ASC Topic 450 Contingencies. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company monitors the stage of progress of its litigation matters to determine if any adjustments are required.

Q. Government grants

Government grants which are received from the IIA by way of participation in research and development that is conducted by the Company, are received in installments as the program progresses based on qualified research spending. Grants received are recognized when the grant becomes receivable, provided there was reasonable assurance that the Company will comply with the conditions attached to the grant and there was reasonable assurance the grant will be received.

Recently issued accounting pronouncements

From time to time, new accounting pronouncements are issued by FASB, or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities About Government Assistance, which requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. The new standard is effective for the Company on January 1, 2022 and only impacts annual financial statement footnote disclosures. Refer to Note 2Q above.

TRANSACTIONS AND BALANCES WITH RELATED PARTIES

12 Months Ended

Dec. 31, 2022

TRANSACTIONS AND BALANCES WITH RELATED PARTIES

NOTE 14 - TRANSACTIONS AND BALANCES WITH RELATED PARTIES

	2022		2021
	For the Years Ended December 31,
	2022		2021
Transactions:
Payroll and related expenses	$	2,067	$	1,912
ESOP expenses to CEO and executive officers		1,172		846
Board of directors fees		300		300
ESOP expenses to directors		301		91
Insurance for directors and executives		722		727
Total	$	4,562	$	3,876

	2022		2021
	As of December 31,
	2022		2021
Balances:
Bonus to CEO and executive offices		581		310
Board of directors fees		75		75
Payroll and related expenses		92		28
Total	$	748	$	413

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	7,890,628	7,108,133
Common stock, shares outstanding	7,890,628	7,108,133

COMMITMENTS AND CONTINGENCIES (Details Narrative) $ / shares in Units, ₪ in Thousands, $ in Thousands										1 Months Ended	12 Months Ended
	Oct. 06, 2022 USD ($)	Oct. 03, 2022 USD ($)	Mar. 31, 2021 USD ($)	Feb. 04, 2020 USD ($)	Apr. 28, 2019 USD ($)	May 25, 2018 USD ($) shares	Jan. 04, 2018 USD ($) $ / shares	Jan. 04, 2018 ILS (₪)	Jan. 04, 2018 USD ($) $ / shares	Jun. 30, 2012	Dec. 31, 2022 USD ($)	Jun. 10, 2021 USD ($)
Loss Contingencies [Line Items]
Stock issued during period, value, new issues											$ 4,324
Net loss on trading of common stock				$ 151
Joseph Mona [Member]
Loss Contingencies [Line Items]
Purchase price of plaintiffs			$ 485
Device [Member]
Loss Contingencies [Line Items]
Royalties percent	3.00%
Integrated Product [Member]
Loss Contingencies [Line Items]
Royalties percent	1.50%
Securities Purchase Agreement [Member]
Loss Contingencies [Line Items]
Purchase price of plaintiffs											$ 6,750
Israeli Innovation Authority [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalties payable as percentage of future sales											3.00%
Israeli Innovation Authority [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalties payable as percentage of future sales											3.50%
Israeli Innovation Authority [Member] \| CardioSert Ltd [Member]
Loss Contingencies [Line Items]
Repayment of government grants									$ 530
Israeli Innovation Authority [Member] \| Nitiloop [Member]
Loss Contingencies [Line Items]
Repayment of government grants	$ 925
Technion Research and Development Foundation Limited [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalties payable as percentage of future sales										1.50%
Technion Research and Development Foundation Limited [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalties payable as percentage of future sales										3.00%
CardioSert Ltd [Member] \| Technology [Member]
Loss Contingencies [Line Items]
Additional cash payment						$ 250	$ 50
Number of common shares issued for acquisition \| shares						6,738
Number of common shares issued for acquisition, value						$ 74
Buy back amount per patent \| $ / shares							$ 1.00		$ 1.00
Consulting fee description							CardioSert agreed to assist Microbot Israel in the development of the Technology for a minimum of one year, for a monthly consultation fee of NIS40 (or approximately US$11.37, based on an exchange rate of NIS 3.519 to the dollar) covering up to 60 consulting hours per month	CardioSert agreed to assist Microbot Israel in the development of the Technology for a minimum of one year, for a monthly consultation fee of NIS40 (or approximately US$11.37, based on an exchange rate of NIS 3.519 to the dollar) covering up to 60 consulting hours per month
Monthly consultation fee \| ₪								₪ 40
Monthly consultation fee in USD \| $ / shares							$ 11.37
Currency exchange rate, description							exchange rate of NIS 3.519 to the dollar	exchange rate of NIS 3.519 to the dollar
CardioSert Ltd [Member] \| Minimum [Member] \| Technology [Member]
Loss Contingencies [Line Items]
Investments							$ 2,000		$ 2,000
H.C. Wainwright & Co. LLC [Member]
Loss Contingencies [Line Items]
Monthly consultation fee		$ 565
H.C. Wainwright & Co. LLC [Member] \| At-the-Market Offering Agreement [Member]
Loss Contingencies [Line Items]
Offering costs												$ 10,000
Stock issued during period, value, new issues	$ 8,000
Alliance Investment Management, Ltd. [Member]
Loss Contingencies [Line Items]
Litigation settlement					$ 468
2013 Through June 30, 2022 [Member] \| Israeli Innovation Authority [Member]
Loss Contingencies [Line Items]
Total grants obtained											$ 1,500

TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)

12 Months Ended

Dec. 31, 2022

	2022		2021
	For the Years Ended December 31,
	2022		2021
Transactions:
Payroll and related expenses	$	2,067	$	1,912
ESOP expenses to CEO and executive officers		1,172		846
Board of directors fees		300		300
ESOP expenses to directors		301		91
Insurance for directors and executives		722		727
Total	$	4,562	$	3,876

	2022		2021
	As of December 31,
	2022		2021
Balances:
Bonus to CEO and executive offices		581		310
Board of directors fees		75		75
Payroll and related expenses		92		28
Total	$	748	$	413

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)

12 Months Ended

Dec. 31, 2022

Prepaid Expenses And Other Current Assets

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS

	2022		2021
	As of December 31,
	2022		2021

Amounts due from government institutions	$	103	$	174
Prepaid expenses		429		126
	$	532	$	300

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 113,393	$ 109,483
Operation lease liabilities	105	156
Accrued vacation pay	71	45
Total deferred tax assets	113,569	110,684
Less: valuation allowance	(113,455)	(110,536)
Net deferred tax assets	114	148
Operating leases, right-of-use assets	(114)	(148)
Total deferred tax liabilities	(114)	(148)
Total net deferred tax assets

SCHEDULE OF RELATED PARTY TRANSACTION AND BALANCES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Payroll and related expenses	$ 2,067	$ 1,912
ESOP expenses to CEO and executive officers	1,172	846
Board of directors fees	300	300
ESOP expenses to directors	301	91
Insurance for directors and executives	722	727
Total	4,562	3,876
Bonus to CEO and executive offices	581	310
Board of directors fees	75	75
Payroll and related expenses	92	28
Total	$ 748	$ 413

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating activities:
Net loss	$ (13,168)	$ (11,313)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	102	76
Unrealized gain from marketable securities	(12)
Loss on disposal of property and equipment	5
Share-based compensation expense	1,752	1,386
Changes in assets and liabilities:
Prepaid expenses and other assets	13	177
Other payables and accrued liabilities	(241)	320
Net cash flows used in operating activities	(11,549)	(9,354)
Investing activities:
Short-term deposit	(3)
Purchase of property and equipment	(84)	(69)
Proceeds from sale of investment		270
Purchase of marketable securities	(3,749)
Proceeds from sales of marketable security		2,999
Net cash flows provided by (used in) investing activities	(3,836)	3,200
Financing activities:
Issuance of common stock and warrants net of issuance costs	4,324
Net cash flows provided by financing activities	4,324
Decrease in cash, cash equivalents and restricted cash	(11,061)	(6,154)
Cash, cash equivalents and restricted cash at beginning of period	13,580	19,734
Cash, cash equivalents and restricted cash at ending of period	2,519	13,580
Supplemental disclosure of cash flow information:
Cash received from interest	51	1
Right-of-use assets and lease liability	$ 103	$ 69

SHARE CAPITAL (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Oct. 21, 2022	Oct. 03, 2022	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares issued			7,890,628	7,108,133
Common stock, shares outstanding			7,890,628	7,108,133
Warrants exercise price	$ 0.0001
Stock-based employee compensation			$ 1,752	$ 1,386
Aggregate intrinsic value of outstanding options			185	974
Aggregate intrinsic value of exercisable options			185	$ 815
Unrecognized compensation costs, net of expected forfeitures			$ 2,036
Unrecognized compensation weighted average period			2 years 14 days
H.C. Wainwright & Co. LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price		$ 6.11
Class of warrants		51,125
Professional service fees		$ 565
Warrant term		5 years
Warrant issued, descriptions		Upon any exercise for cash of any preferred investment options issued to investors in the offering, the Company obligate to pay 7% percent of the aggregate gross exercise price of the warrants issued in the Offering and shall issue to Wainwright (or its designees), within five (5) business days of the Company’s receipt of the exercise price, warrants to purchase that number of shares of common stock of the Company equal to five (5.0%) percent of the aggregate number of such shares of common stock underlying the preferred investment options that have been so exercised.
Series A Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate shares of common stock	1,022,495
Share price per share	$ 4.64
Series B Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate shares of common stock	1,022,495
Share price per share	$ 4.64
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate shares of common stock			782,495
Common Stock [Member] \| Mr. Harel Gadot [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted			260,000	190,000
Weighted-average exercise price per share, granted				$ 8.48
Stock option vested term			3 years	2 years
Stock-based employee compensation				$ 646
Common Stock [Member] \| Mr. Harel Gadot [Member] \| Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-average exercise price per share, granted			$ 3.73
Common Stock [Member] \| Mr. Harel Gadot [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-average exercise price per share, granted			$ 6.48
Common Stock [Member] \| Employees Consultants and Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted			270,822	231,426
Stock option vested term			3 years	3 years
Stock-based employee compensation				$ 740
Common Stock [Member] \| Employees Consultants and Directors [Member] \| Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-average exercise price per share, granted			$ 3.73	$ 6.72
Common Stock [Member] \| Employees Consultants and Directors [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted-average exercise price per share, granted			$ 6.48	$ 7.26
Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate shares of common stock	782,495
Exercise price	$ 4.89
Purchase Agreement [Member] \| Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price	$ 4.8899
Class of warrants	240,000
Proceeds from warrants offerings	$ 5,000

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases
2023	$ 312
2024	181
2025	2
Total future lease payments	495
Less imputed interest	(33)
Total lease liability balance	$ 462

GENERAL AND ADMINISTRATIVE EXPENSES

12 Months Ended

Dec. 31, 2022

General And Administrative Expenses

GENERAL AND ADMINISTRATIVE EXPENSES

NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES

	2022		2021
	For the Years Ended December 31,
	2022		2021
Payroll and related expenses	$	1,813	$	1,391
Government fees		35		170
Share-based compensation		1,365		1,203
Professional services		998		1,298
Insurance		733		732
Public and investor relations		220		203
Office and maintenance expenses		120		108
Travel		180		42
Other		81		57
General and administrative expenses	$	5,545	$	5,204

GENERAL (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
GENERAL (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of incorporation	Aug. 02, 1988
Cash equivalents and marketable securities	$ 8,202	$ 15,492

SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares	12 Months Ended
SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Series A (2013) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants	183	183
Exercise price	$ 2,754.00
Exercisable Through	April 9, 2023
Series B (2016) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		2,770
Exercise price	$ 40.50
Exercisable Through	March 14, 2022
Warrant to Underwriters 1.2019 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		8,082
Exercise price	$ 8.13
Exercisable Through	July 14, 2022
Warrant to Underwriters 1.2019 One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants		29,500
Exercise price	$ 12.50
Exercisable Through	July 15, 2022
Warrant to Underwriters 12.2019 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants	45,643	45,643
Exercise price	$ 13.13
Exercisable Through	June 25, 2023
Warrant to Underwriters 12.2019 One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants	47,619	47,619
Exercise price	$ 13.13
Exercisable Through	June 27, 2023
Warrant to Underwriters 12.2019 Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants	45,045	45,045
Exercise price	$ 13.88
Exercisable Through	June 30, 2023
Series A 10.2022 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants	1,022,495
Exercise price	$ 4.64
Exercisable Through	October 25, 2027
Series B 10.2022 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants	1,022,495
Exercise price	$ 4.64
Exercisable Through	October 25, 2024
Warrant to Underwriters 10.2022 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding warrants	51,125
Exercise price	$ 6.11
Exercisable Through	October 21, 2027

GENERAL

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL

NOTE 1 - GENERAL

Description of business:

Microbot Medical Inc. (the “Company”) is a pre-clinical medical device company specializing in the research, design and development of next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients.

The Company incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc.

On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”.

The Company and its subsidiary are sometimes collectively referred to as the “Company” as the context may require.

Risk Factors:

To date, the Company has not generated revenues from its operations. As of December 31, 2022, the Company had cash equivalents and marketable securities balance of approximately $8,202 excluding encumbered cash, which management believes is sufficient to fund its operations for additional 4 months form the date of this annual report. As of the issuance date, there is a substantial doubt as to the Company’s ability to continue as a going concern.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Due to continuing research and development activities, the Company expects to continue to incur additional losses for the foreseeable future. While management of the Company believes that it has sufficient funds until August 2023, the Company will seek to raise additional funds through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company.

Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Research and development	$ (7,736)	$ (6,153)
General and administrative	(5,545)	(5,204)
Operating loss	(13,281)	(11,357)
Financing income, net	118	44
Capital loss	(5)
Net loss	$ (13,168)	$ (11,313)
Basic and diluted net loss per share	$ (1.81)	$ (1.59)
Basic and diluted weighted average common shares outstanding	7,260,344	7,108,133

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES

12 Months Ended

Dec. 31, 2022

Cash and Cash Equivalents [Abstract]

CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES

NOTE 3 – CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES

The following table sets forth our cash, cash equivalents and marketable securities as of December 31, 2022 and 2021:

	2022		2021
	As of December 31,
	2022		2021
Cash and cash equivalents:
Cash	$	1,195	$	13,493
U.S. treasury securities		1,247		-
Total cash and cash equivalents	$	2,442	$	13,493

Marketable securities:
Money market mutual funds	$	1,999	$	1,999
U.S. treasury securities		3,761		-
Total marketable securities	$	5,760	$	1,999

Total cash and cash equivalents and marketable securities	$	8,202	$	15,492

The unrealized gains on our marketable securities were $12 and less than $1 for the years ended December 31, 2022 and 2021, respectively.

Treasuries have contractual maturities of less than 12 months.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 2,442	$ 13,493
Marketable securities	5,760	1,999
Short-term deposit	3
Restricted cash	77	87
Prepaid expenses and other current assets	532	300
Total current assets	8,814	15,879
Property and equipment, net	221	244
Operating right-of-use assets	502	644
Total assets	9,537	16,767
Current liabilities:
Accounts payables	116	279
Lease liabilities	283	278
Accrued liabilities	1,670	1,427
Total current liabilities	2,069	1,984
Non-current liabilities:
Long-term lease liabilities	179	402
Total liabilities	2,248	2,386
Commitments and contingencies
Stockholders’ equity:
Common stock; $0.01 par value; 60,000,000 shares authorized as of December 31, 2022 and 2021; 7,890,628 and 7,108,133 shares issued and outstanding as of December 31, 2022 and 2021, respectively.	80	72
Additional paid-in capital	75,970	69,902
Accumulated deficit	(68,761)	(55,593)
Total stockholders’ equity	7,289	14,381
Total liabilities and stockholders’ equity	$ 9,537	$ 16,767

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Basis of presentation

Basis of presentation:

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Financial statement in U.S. dollars

Financial statement in U.S. dollars:

Principles of consolidation

Principles of consolidation:

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. Inter-company balances and transactions have been eliminated in consolidation.

Cash and cash equivalents

Cash and cash equivalents:

Restricted cash

Restricted cash:

Restricted cash as of December 31, 2022 and 2021 included an $77 and $87, respectively, collateral account for the Company’s leases agreements and credit line from the bank.

Fair value of financial instruments

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Fair value of financial instruments:

The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments.

Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Concentrations of credit risk

Concentrations of credit risk

Property and equipment

Property and equipment:

	%

Research equipment and software		25-33
Furniture and office equipment		7
Leasehold improvements		Over the lease period

Liabilities due to termination of employment agreements

Liabilities due to termination of employment agreements:

Basic and diluted net loss per share

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Basic and diluted net loss per share:

Research and development expenses

Research and development expenses

Share-based compensation

Share-based compensation:

Income Taxes

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Income Taxes:

Marketable securities

Marketable securities:

Leases

Leases

Contingencies

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Contingencies

Government grants

Q. Government grants

Recently issued accounting pronouncements

Recently issued accounting pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT

	%

Research equipment and software		25-33
Furniture and office equipment		7
Leasehold improvements		Over the lease period

BASIC AND DILUTED NET LOSS PER SHARE

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

BASIC AND DILUTED NET LOSS PER SHARE

NOTE 11 - BASIC AND DILUTED NET LOSS PER SHARE

The basic and diluted net loss per share and weighted average number of shares of common stock used in the calculation of basic and diluted net loss per share were presented in the consolidated statements of comprehensive loss for the years ended December 31, 2022 and 2021.

Due to the net loss to common stockholders in each of the periods presented above, diluted loss per share was computed without consideration to potentially dilutive instruments as their inclusion would have been anti-dilutive. As of December 31, 2022 and 2021, potentially dilutive securities excluded from the diluted loss per share calculation are as follows:

	For the Years Ended December 31,
	2022		2021

Series A and B warrants 2013 and 2016		183		2,953
Warrant to underwriters 12.2019		138,307		175,889
Series A and B warrants 10.2022		2,044,990		-
Warrant to underwriters 10.2022		51,125		-
Outstanding options to purchase common stock		1,507,137		997,148

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Cash payments and expenses	$ 344	$ 330

SCHEDULE OF STOCK OPTIONS OUTSTANDING (Details) - $ / shares

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 0.01

Stock options outstanding

1,507,137

997,148

Weighted average remaining contractual life

7 years 7 months 6 days

Stock options exercisable

899,609

568,053

Exercise Price One [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 3.73

Stock options outstanding

211,000

Weighted average remaining contractual life

10 years

Stock options exercisable

Exercise Price Two [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 4.20

Stock options outstanding

77,846

Weighted average remaining contractual life

2 years

3 years

Stock options exercisable

77,846

Exercise Price Three [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 4.80

Stock options outstanding

32,500

Weighted average remaining contractual life

9 years 7 months 6 days

Stock options exercisable

Exercise Price Four [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 5.06

Stock options outstanding

15,808

Weighted average remaining contractual life

6 years 9 months 18 days

7 years 9 months 18 days

Stock options exercisable

15,808

11,064

Exercise Price Five [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 5.71

Stock options outstanding

99,823

Weighted average remaining contractual life

9 years 8 months 12 days

Stock options exercisable

Exercise Price Six [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 5.95

Stock options outstanding

17,503

Weighted average remaining contractual life

6 years 7 months 6 days

7 years 7 months 6 days

Stock options exercisable

17,503

13,564

Exercise Price Seven [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 6.16

Stock options outstanding

31,492

Weighted average remaining contractual life

7 years 6 months

8 years 6 months

Stock options exercisable

26,282

16,834

Exercise Price Eight [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 6.48

Stock options outstanding

182,500

Weighted average remaining contractual life

9 years 1 month 6 days

Stock options exercisable

59,312

Exercise Price Nine [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 6.72

Stock options outstanding

117,500

125,000

Weighted average remaining contractual life

8 years 4 months 24 days

9 years 4 months 24 days

Stock options exercisable

64,624

31,249

Exercise Price Ten [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 7.00

Stock options outstanding

81,426

Weighted average remaining contractual life

8 years 9 months 18 days

9 years 9 months 18 days

Stock options exercisable

38,676

Exercise Price Eleven [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 7.22

Stock options outstanding

11,084

Weighted average remaining contractual life

7 years 10 months 24 days

8 years 10 months 24 days

Stock options exercisable

7,756

4,432

Exercise Price Twelve [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 7.26

Stock options outstanding

20,000

25,000

Weighted average remaining contractual life

8 years 9 months 18 days

9 years 9 months 18 days

Stock options exercisable

8,000

Exercise Price Thirteen [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 8.16

Stock options outstanding

4,902

Weighted average remaining contractual life

7 years 7 months 6 days

8 years 7 months 6 days

Stock options exercisable

3,799

2,328

Exercise Price Fourteen [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 8.48

Stock options outstanding

190,000

Weighted average remaining contractual life

8 years 1 month 6 days

9 years 1 month 6 days

Stock options exercisable

166,250

Exercise Price Fifteen [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 8.60

Stock options outstanding

9,304

Weighted average remaining contractual life

6 years 1 month 6 days

7 years 1 month 6 days

Stock options exercisable

9,304

Exercise Price Sixteen [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 9.00

Stock options outstanding

10,000

Weighted average remaining contractual life

5 years 7 months 6 days

6 years 7 months 6 days

Stock options exercisable

10,000

Exercise Price Seventeen [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 9.64

Stock options outstanding

166,666

Weighted average remaining contractual life

7 years 2 months 12 days

8 years 2 months 12 days

Stock options exercisable

166,666

Exercise Price Eighteen [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 15.30

Stock options outstanding

35,199

38,533

Weighted average remaining contractual life

5 years

6 years

Stock options exercisable

35,199

38,533

Exercise Price Nineteen [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

$ 15.75

Stock options outstanding

131,007

Weighted average remaining contractual life

4 years 8 months 12 days

5 years 8 months 12 days

Stock options exercisable

131,007

124,656

Exercise Price Twenty [Member]

Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]

Exercise price

^[1]

Stock options outstanding

61,577

Weighted average remaining contractual life

3 years 3 months 18 days

4 years 3 months 18 days

Stock options exercisable

61,577

[1]	Less than $0.01.

SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Expected volatility, minimum	111.20%	118.30%
Expected volatility, maximum	161.70%	134.30%
Risk-free interest, minimum	1.70%	0.40%
Risk-free interest, maximum	3.70%	1.20%
Dividend yield
Expected terms (years)	6 years 2 months 12 days	5 years 3 months 18 days

TAXES ON INCOME

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

TAXES ON INCOME

NOTE 15 - TAXES ON INCOME

The Company is subject to income taxes under the Israeli and U.S. tax laws:

Corporate tax rates

The Company is subject to U.S. federal tax rate of 21% for the years ended December 31, 2022 and 2021.

The Company has not been audited by the Internal Revenue Service since its incorporation.

As of December 31, 2022 and 2021, the Company has generated accumulated net operating losses in the U.S. of approximately $502,053 and $496,950, respectively. Net operating losses in the United States are available through 2035. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.

Microbot Israel is subject to Israeli corporate tax rate of 23% for the years ended 2022 and 2021. Microbot Israel has not received a final tax assessment since 2016.

As of December 31, 2022 and 2021, Microbot Israel has generated accumulated net operating losses in Israel of approximately $34,688 and $26,623, respectively, which may be carried forward and offset against taxable income in the future for an indefinite period.

The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts.


	For the Years Ended December 31,
	2022			2021

Net operating loss carryforwards	$	113,393		$	109,483
Operation lease liabilities		105			156
Accrued vacation pay		71			45
Total deferred tax assets		113,569			110,684
Less: valuation allowance		(113,455	)		(110,536	)
Net deferred tax assets		114			148

Operating leases, right-of-use assets		(114	)		(148	)
Total deferred tax liabilities		(114	)		(148	)
Total net deferred tax assets	$	-		$	-

Reconciliation of Income Taxes:

The following is a reconciliation of the taxes on income assuming that all income is taxed at the ordinary statutory corporate tax rate in Israel and the effective income tax rate:

	For the Years Ended December 31,
	2022			2021

Net loss in Israel	$	8,065		$	6,853
Net loss in U.S.	$	5,103		$	4,460
Statutory tax rate		21%-23%			21%-23%
Income Tax under statutory tax rate		2,922			2,513
Change in valuation allowance		(2,922	)		(2,513	)
Actual provision for income tax	$	-		$	-

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)	12 Months Ended
	Dec. 31, 2022
Research Equipment and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	25 years
Research Equipment and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	33 years
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	Over the lease period

SUMMARY OF STOCK OPTION ACTIVITY (Details) - Employees and Directors [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of stock options outstanding, Outstanding at beginning of period	997,148	575,722
Weighted average exercise price, Outstanding at beginning of period	$ 8.48	$ 9.14
Number of stock options outstanding, Granted	530,822	421,426
Weighted average exercise price, Granted	$ 5.14	$ 7.60
Number of stock options outstanding, cancelled	(20,833)
Weighted average exercise price, cancelled	$ 8.16
Number of stock options outstanding, Outstanding at end of period	1,507,137	997,148
Weighted average exercise price, Outstanding at end of period	$ 7.31	$ 8.48
Number of stock options outstanding, Vested at end of period	899,609	568,053
Weighted average exercise price, Vested at end of period	$ 8.52	$ 9.08

SHARE CAPITAL

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

SHARE CAPITAL

NOTE 10 - SHARE CAPITAL

Share Capital Developments

As of December 31, 2022, and 2021, the Company has 7,890,628 and 7,108,133 shares of common stock issued and outstanding, respectively.

On October 21, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Company issued and sold, in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market (the “Registered Offering”), (i) an aggregate of 782,495 shares of Common Stock, at an offering price of $4.89 per share and (ii) pre-funded warrants exercisable for up to 240,000 shares of Common Stock (the “Pre-Funded Warrants”) to the Investor at an offering price of $4.8899 per Pre-Funded Warrant, for aggregate gross proceeds from the Offerings (as defined below) of approximately $5,000 before deducting the placement agent fee (as described below) and related offering expenses.

Each Pre-Funded Warrant represents the right to purchase one share of Common Stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full.

In a concurrent private placement (the “Private Placement” and, together with the Registered Offering, the “Offerings”), the Company issued to the Investor (i) Series A preferred investment options to purchase up to 1,022,495 shares of Common Stock (the “Series A Warrants”) at an exercise price of $4.64 per share and (ii) Series B preferred investment options to purchase up to 1,022,495 shares of Common Stock (the “Series B Warrants”) at an exercise price of $4.64 per share. Each Series A Warrant is exercisable immediately and will expire five years from the initial exercise date. Each Series B Warrant is exercisable immediately and will expire two years from the initial exercise date.

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC 480 and FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under FASB ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

The Company analyzed the accounting treatment for the Pre-funded Warrants and for the Common Warrants. The Common Stocks of the Company are recognized as equity under the requirements of Accounting Standard Codification Topic 505 Equity (ASC 505). Based on the Company’s analysis the Warrants were classified as equity.

On October 3, 2022 and in connection with the Offerings, the Company entered into an engagement letter with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement. As compensation for such placement agent services, the Company paid Wainwright aggregate cash fees and reimbursed Wainwright for its expenses aggregating approximately $565. The Company also issued to Wainwright or its designees warrants to purchase 51,125 shares of Common Stock (the “Wainwright Warrants”). The Wainwright Warrants have a term of five years from the commencement of sales in the Offerings, and have an exercise price of $6.11 per share. Upon any exercise for cash of any preferred investment options issued to investors in the offering, the Company obligate to pay 7% percent of the aggregate gross exercise price of the warrants issued in the Offering and shall issue to Wainwright (or its designees), within five (5) business days of the Company’s receipt of the exercise price, warrants to purchase that number of shares of common stock of the Company equal to five (5.0%) percent of the aggregate number of such shares of common stock underlying the preferred investment options that have been so exercised.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

The Company analyzed the accounting treatment for the Wainwright Warrants issued to Wainwright. Since the Company did not identify any features causing liability classification of the Wainwright Warrants according to ASC 718, it concluded that the Wainwright Warrants are equity-classified awards.

Employee Stock Option Grants

During the year ended December 31, 2021, the Company granted to Mr. Harel Gadot, the Company’s Chairman of the Board, President and CEO, options to purchase an aggregate of 190,000 shares of the Company’s common stock, at an exercise price per share of $8.48. The stock options vest over a period of 2 years as outlined in the option agreements evidencing such grants. As a result, the Company recognized compensation expenses for the year ended December 31, 2021, in the total amount of $646.

During the year ended December 31, 2021, the Company granted to certain employees and consultants and directors, options to purchase an aggregate of 231,426 shares of the Company’s common stock, at an exercise price per share of $6.72 - $7.26. The stock options vest over a period of 3 years as outlined in the option agreements evidencing such grants. As a result, the Company recognized compensation expenses for the year ended December 31, 2021, in the total amount of $740.

During the year ended December 31, 2022, the Company granted to Mr. Harel Gadot, the Company’s Chairman of the Board, President and CEO, options to purchase an aggregate of 260,000 shares of the Common Stock, at an exercise price per share of $3.73-$6.48. The stock options vest over a period of three years as outlined in the option agreements evidencing such grants.

During the year ended December 31, 2022, the Company granted to certain employees, consultants and directors, options to purchase an aggregate of 270,822 shares of the Common Stock, at an exercise price per share of $3.73-$6.48. The stock options vest over a period of three years as outlined in the option agreements evidencing such grants.

A summary of the Company’s option activity related to options to employees and directors, and related information is as follows:

SUMMARY OF STOCK OPTION ACTIVITY

	For the Year Ended December 31, 2022
	Number of stock options			Weighted average exercise price

Outstanding as of December 31, 2021		997,148		$	8.48
Granted		530,822			5.14
Cancelled		(20,833	)		8.16
Outstanding as of December 31, 2022		1,507,137		$	7.31

Vested as of December 31, 2022		899,609		$	8.52

	For the Year Ended December 31, 2021
	Number of stock options		Weighted average exercise price

Outstanding as of December 31, 2020		575,722	$	9.14
Granted		421,426		7.60
Outstanding as of December 31, 2021		997,148	$	8.48

Vested as of December 31, 2021		568,053	$	9.08

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

The Company recognizes forfeitures of outstanding options as they occur.

The intrinsic value is calculated as the difference between the fair market value of the common stock and the exercise price, multiplied by the number of in-the-money stock options on those dates that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates as of December 31, 2022 and December 31, 2021, respectively.

As of December 31, 2022, and 2021, the aggregate intrinsic value of the outstanding options is $185 and $974 respectively, and the aggregate intrinsic value of the exercisable options is $185 and $815, respectively.

As of December 31, 2022, there were approximately $2,036 of total unrecognized compensation costs related to unvested share-based compensation awards granted under the Share Incentive Plan. The costs are expected to be recognized over a weighted average period of 2.039 years

The stock options outstanding as of December 31, 2022 and December 31, 2021, summarized by exercise prices, are as follows:

SCHEDULE OF STOCK OPTIONS OUTSTANDING

Exercise price $	Stock options outstanding as of December 31, 2022		Stock options outstanding as of December 31, 2021		Weighted average remaining contractual life – years as of December 31, 2022		Weighted average remaining contractual life – years as of December 31, 2021		Stock options exercisable as of December 31, 2022		Stock options exercisable as of December 31, 2021
3.73		211,000		-		10		-		-		-
4.20		77,846		77,846		2.0		3.0		77,846		77,846
4.80		32,500		-		9.6		-		-		-
5.06		15,808		15,808		6.8		7.8		15,808		11,064
5.71		99,823		-		9.7		-		-		-
5.95		17,503		17,503		6.6		7.6		17,503		13,564
6.16		31,492		31,492		7.5		8.5		26,282		16,834
6.48		182,500		-		9.1		-		59,312		-
6.72		117,500		125,000		8.4		9.4		64,624		31,249
7.00		81,426		81,426		8.8		9.8		38,676		-
7.22		11,084		11,084		7.9		8.9		7,756		4,432
7.26		20,000		25,000		8.8		9.8		8,000		-
8.16		4,902		4,902		7.6		8.6		3,799		2,328
8.48		190,000		190,000		8.1		9.1		166,250		-
8.60		9,304		9,304		6.1		7.1		9,304		9,304
9.00		10,000		10,000		5.6		6.6		10,000		10,000
9.64		166,666		166,666		7.2		8.2		166,666		166,666
15.30		35,199		38,533		5.0		6.0		35,199		38,533
15.75		131,007		131,007		4.7		5.7		131,007		124,656
(*) -		61,577		61,577		3.3		4.3		61,577		61,577
		1,507,137		997,148		7.6		7.6		899,609		568,053

(*)	Less than $0.01.

Compensation expense recorded by the Company for its stock-based employee compensation awards in accordance with ASC 718-10 for the years ended December 31, 2022 and 2021 was $1,752 and $1,386, respectively.

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

Employee Stock Option Grants

The grant date fair values of stock options granted in the years ended December 31, 2022 and 2021 were estimated using the Black-Scholes valuation model with the following:

For the Years Ended December 31,

2022 2021

Expected volatility
111.2%-161.7%
118.3%-134.3%

Risk-free interest 1.7%- 3.7% 0.4%-1.2%

Dividend yield -% -%

Expected terms (years) 6.2 5.3

Warrants

The remaining outstanding warrants and terms as of December 31, 2022 and 2021 are as follows:

SCHEDULE OF WARRANTS OUTSTANDING

Issuance date Outstanding and exercisable as of December 31, 2022 Outstanding and exercisable as of December 31, 2021 Exercise Price Exercisable Through

Series A (2013) 183 183 $ 2,754.00 April 9, 2023

Series B (2016) - 2,770 $ 40.50 March 14, 2022

Warrant to underwriters 1.2019 - 8,082 $ 8.13 July 14, 2022

Warrant to underwriters 1.2019 - 29,500 $ 12.50 July 15, 2022

Warrant to underwriters 12.2019 45,643 45,643 $ 13.13 June 25, 2023

Warrant to underwriters 12.2019 47,619 47,619 $ 13.13 June 27, 2023

Warrant to underwriters 12.2019 45,045 45,045 $ 13.88 June 30, 2023

Series A 10.2022 1,022,495 - $ 4.64 October 25, 2027

Series B 10.2022 1,022,495 - $ 4.64 October 25, 2024

Warrant to underwriters 10.2022 51,125 - $ 6.11 October 21, 2027

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2022

Payables and Accruals [Abstract]

ACCRUED LIABILITIES

NOTE 8 - ACCRUED LIABILITIES

SUMMARY OF ACCRUED LIABILITIES

	2022		2021
	As of December 31,
	2022		2021

Employee-related liabilities	$	1,372	$	1,031
Other current liabilities		298		396
Total Accrued Liabilities	$	1,670	$	1,427

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES

The following table summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of December 31, 2022 and 2021:

	As of December 31, 2022
	Total		Level 1		Level 2		Level 3

Cash equivalents:
U.S. treasury securities	$	1,247	$	1,247	$	-	$	-

Marketable securities:
U.S. treasury securities	$	3,761	$	3,761	$	-	$	-
Money market mutual funds		1,999		1,999		-		-
	$	5,760	$	5,760	$	-	$	-

	As of December 31, 2021
	Total		Level 1		Level 2		Level 3

Cash equivalents:
Money market funds	$	- (*)	$	- (*)	$	-	$	-

Marketable securities:
Money market mutual funds	$	1,999	$	1,999	$	-	$	-

(*)

Reclassified

SHARE CAPITAL (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

SUMMARY OF STOCK OPTION ACTIVITY

A summary of the Company’s option activity related to options to employees and directors, and related information is as follows:

SUMMARY OF STOCK OPTION ACTIVITY

	For the Year Ended December 31, 2022
	Number of stock options			Weighted average exercise price

Outstanding as of December 31, 2021		997,148		$	8.48
Granted		530,822			5.14
Cancelled		(20,833	)		8.16
Outstanding as of December 31, 2022		1,507,137		$	7.31

Vested as of December 31, 2022		899,609		$	8.52

	For the Year Ended December 31, 2021
	Number of stock options		Weighted average exercise price

Outstanding as of December 31, 2020		575,722	$	9.14
Granted		421,426		7.60
Outstanding as of December 31, 2021		997,148	$	8.48

Vested as of December 31, 2021		568,053	$	9.08

SCHEDULE OF STOCK OPTIONS OUTSTANDING

The stock options outstanding as of December 31, 2022 and December 31, 2021, summarized by exercise prices, are as follows:

SCHEDULE OF STOCK OPTIONS OUTSTANDING

Exercise price $	Stock options outstanding as of December 31, 2022		Stock options outstanding as of December 31, 2021		Weighted average remaining contractual life – years as of December 31, 2022		Weighted average remaining contractual life – years as of December 31, 2021		Stock options exercisable as of December 31, 2022		Stock options exercisable as of December 31, 2021
3.73		211,000		-		10		-		-		-
4.20		77,846		77,846		2.0		3.0		77,846		77,846
4.80		32,500		-		9.6		-		-		-
5.06		15,808		15,808		6.8		7.8		15,808		11,064
5.71		99,823		-		9.7		-		-		-
5.95		17,503		17,503		6.6		7.6		17,503		13,564
6.16		31,492		31,492		7.5		8.5		26,282		16,834
6.48		182,500		-		9.1		-		59,312		-
6.72		117,500		125,000		8.4		9.4		64,624		31,249
7.00		81,426		81,426		8.8		9.8		38,676		-
7.22		11,084		11,084		7.9		8.9		7,756		4,432
7.26		20,000		25,000		8.8		9.8		8,000		-
8.16		4,902		4,902		7.6		8.6		3,799		2,328
8.48		190,000		190,000		8.1		9.1		166,250		-
8.60		9,304		9,304		6.1		7.1		9,304		9,304
9.00		10,000		10,000		5.6		6.6		10,000		10,000
9.64		166,666		166,666		7.2		8.2		166,666		166,666
15.30		35,199		38,533		5.0		6.0		35,199		38,533
15.75		131,007		131,007		4.7		5.7		131,007		124,656
(*) -		61,577		61,577		3.3		4.3		61,577		61,577
		1,507,137		997,148		7.6		7.6		899,609		568,053

(*)	Less than $0.01.

SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS

The grant date fair values of stock options granted in the years ended December 31, 2022 and 2021 were estimated using the Black-Scholes valuation model with the following:

	For the Years Ended December 31,
	2022		2021
Expected volatility		111.2%-161.7%		118.3%-134.3%
Risk-free interest		1.7%- 3.7%		0.4%-1.2%
Dividend yield		-%		-%
Expected terms (years)		6.2		5.3

SCHEDULE OF WARRANTS OUTSTANDING

The remaining outstanding warrants and terms as of December 31, 2022 and 2021 are as follows:

SCHEDULE OF WARRANTS OUTSTANDING

Issuance date	Outstanding and exercisable as of December 31, 2022		Outstanding and exercisable as of December 31, 2021		Exercise Price		Exercisable Through
Series A (2013)		183		183	$	2,754.00	April 9, 2023
Series B (2016)		-		2,770	$	40.50	March 14, 2022
Warrant to underwriters 1.2019		-		8,082	$	8.13	July 14, 2022
Warrant to underwriters 1.2019		-		29,500	$	12.50	July 15, 2022
Warrant to underwriters 12.2019		45,643		45,643	$	13.13	June 25, 2023
Warrant to underwriters 12.2019		47,619		47,619	$	13.13	June 27, 2023
Warrant to underwriters 12.2019		45,045		45,045	$	13.88	June 30, 2023
Series A 10.2022		1,022,495		-	$	4.64	October 25, 2027
Series B 10.2022		1,022,495		-	$	4.64	October 25, 2024
Warrant to underwriters 10.2022		51,125		-	$	6.11	October 21, 2027

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)

12 Months Ended

Dec. 31, 2022

General And Administrative Expenses

SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES

	2022		2021
	For the Years Ended December 31,
	2022		2021
Payroll and related expenses	$	1,813	$	1,391
Government fees		35		170
Share-based compensation		1,365		1,203
Professional services		998		1,298
Insurance		733		732
Public and investor relations		220		203
Office and maintenance expenses		120		108
Travel		180		42
Other		81		57
General and administrative expenses	$	5,545	$	5,204

LEASES

12 Months Ended

Dec. 31, 2022

Leases

LEASES

NOTE 6 - LEASES

In November 2019, the Company signed a lease agreement for the period from November 2019 till October 2024. In addition, the Company received an option to extend the lease agreement for additional 5 years.

The monthly lease payments are approximately $16.

To secure the lease payments the Company had issued a bank guarantee of $54 in favor of the facility’s lessor.

Supplemental cash flow information related to operating leases was as follows:

	2022		2021
	For the Years Ended December 31,
	2022		2021
Cash payments and expenses	$	344	$	330

Undiscounted maturities of operating lease payments as of December 31, 2022 are summarized as follows:

	2022
	As of December 31,
	2022
2023	$	312
2024		181
2025		2
Total future lease payments		495
Less imputed interest		(33	)
Total lease liability balance	$	462

	As of December 31,
	2022			2021

Operating leases weighted average remaining lease term (in years)		2			3
Operating leases weighted average discount rate		9	%		9	%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Restricted cash	$ 77	$ 87

SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Payroll and related expenses	$ 2,067	$ 1,912
Share-based compensation	1,752	1,386
Research and development expense	7,736	6,153
Research and Development Expense [Member]
Payroll and related expenses	3,558	3,030
Share-based compensation	387	183
Professional services	2,097	1,532
Materials	559	703
Patents	341	251
Rent	224	206
Office and maintenance expenses	100	123
Depreciation	102	72
Other	368	53
Research and development expense	$ 7,736	$ 6,153

SUBSEQUENT EVENT

12 Months Ended

Dec. 31, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENT

NOTE 16 – SUBSEQUENT EVENT

On February 13, 2023, 240,000 pre-funded warrants were exercised to shares of Common Stock (the “Pre-Funded Warrants”) in exercise price of $0.0001 per share.

SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES (Details)	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating leases weighted average remaining lease term (in years)	2 years	3 years
Operating leases weighted average discount rate	9.00%	9.00%

SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Payroll and related expenses	$ 2,067	$ 1,912
Share-based compensation	1,752	1,386
General and administrative expenses	5,545	5,204
General and Administrative Expense [Member]
Payroll and related expenses	1,813	1,391
Government fees	35	170
Share-based compensation	1,365	1,203
Professional services	998	1,298
Insurance	733	732
Public and investor relations	220	203
Office and maintenance expenses	120	108
Travel	180	42
Other	81	57
General and administrative expenses	$ 5,545	$ 5,204

SUBSEQUENT EVENT (Details Narrative) - Subsequent Event [Member]	Feb. 13, 2023 $ / shares shares
Subsequent Event [Line Items]
Aggregate shares of common stock \| shares	240,000
Exercise price \| $ / shares	$ 0.0001

BASIC AND DILUTED NET LOSS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES EXCLUDED FROM DILUTED LOSS PER SHARE

	For the Years Ended December 31,
	2022		2021

Series A and B warrants 2013 and 2016		183		2,953
Warrant to underwriters 12.2019		138,307		175,889
Series A and B warrants 10.2022		2,044,990		-
Warrant to underwriters 10.2022		51,125		-
Outstanding options to purchase common stock		1,507,137		997,148

PREPAID EXPENSES AND OTHER CURRENT ASSETS

12 Months Ended

Dec. 31, 2022

Prepaid Expenses And Other Current Assets

PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 5 – PREPAID EXPENSES AND OTHER CURRENT ASSETS

	2022		2021
	As of December 31,
	2022		2021

Amounts due from government institutions	$	103	$	174
Prepaid expenses		429		126
	$	532	$	300

MICROBOT MEDICAL INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

(Except share and per share data)

LEASES (Tables)

12 Months Ended

Dec. 31, 2022

Leases

SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES

Supplemental cash flow information related to operating leases was as follows:

	2022		2021
	For the Years Ended December 31,
	2022		2021
Cash payments and expenses	$	344	$	330

SCHEDULE OF MATURITIES OF LEASE LIABILITIES

Undiscounted maturities of operating lease payments as of December 31, 2022 are summarized as follows:

	2022
	As of December 31,
	2022
2023	$	312
2024		181
2025		2
Total future lease payments		495
Less imputed interest		(33	)
Total lease liability balance	$	462

SCHEDULE OF SUPPLEMENTAL INFORMATION RELATED TO LEASES

	As of December 31,
	2022			2021

Operating leases weighted average remaining lease term (in years)		2			3
Operating leases weighted average discount rate		9	%		9	%

ACCRUED LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2022

Payables and Accruals [Abstract]

SUMMARY OF ACCRUED LIABILITIES

	2022		2021
	As of December 31,
	2022		2021

Employee-related liabilities	$	1,372	$	1,031
Other current liabilities		298		396
Total Accrued Liabilities	$	1,670	$	1,427

RESEARCH AND DEVELOPMENT EXPENSES, NET

12 Months Ended

Dec. 31, 2022

Research and Development [Abstract]

RESEARCH AND DEVELOPMENT EXPENSES, NET

NOTE 12 - RESEARCH AND DEVELOPMENT EXPENSES, NET

	2022		2021
	For the Years Ended December 31,
	2022		2021
Payroll and related expenses	$	3,558	$	3,030
Share-based compensation		387		183
Professional services		2,097		1,532
Materials		559		703
Patents		341		251
Rent		224		206
Office and maintenance expenses		100		123
Depreciation		102		72
Other		368		53
Research and development expense	$	7,736	$	6,153

PROPERTY AND EQUIPMENT, NET (Tables)

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

SUMMARY OF PROPERTY AND EQUIPMENT, NET

	As of December 31,
	2022		2021

Cost:
Research equipment and software	$	71	$	68
Leasehold improvement		229		229
Furniture and office equipment		308		236
		608		533
Accumulated Depreciation:
Research equipment and software		63		54
Leasehold improvement		135		89
Furniture and office equipment		189		146
		387		289
	$	221	$	244

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2020	$ 72	$ 68,516	$ (44,280)	$ 24,308
Balance, shares at Dec. 31, 2020	7,108,133
Share-based compensation		1,386		1,386
Net loss			(11,313)	(11,313)
Balance at Dec. 31, 2021	$ 72	69,902	(55,593)	14,381
Balance, shares at Dec. 31, 2021	7,108,133
Issuance of common stock and warrants net of issuance costs	$ 8	4,316		4,324
Issuance of common stock and warrants net of issuance costs, shares	782,495
Share-based compensation		1,752		1,752
Net loss			(13,168)	(13,168)
Balance at Dec. 31, 2022	$ 80	$ 75,970	$ (68,761)	$ 7,289
Balance, shares at Dec. 31, 2022	7,890,628

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

TAXES ON INCOME (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
US Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax rate	21.00%	21.00%
Net operating loss carryforwards	$ 502,053	$ 496,950
Israel Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Corporate income tax rate	23.00%	23.00%
Net operating loss carryforwards	$ 34,688	$ 26,623

SUMMARY OF ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Employee-related liabilities	$ 1,372	$ 1,031
Other current liabilities	298	396
Total Accrued Liabilities	$ 1,670	$ 1,427

CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Unrealized gains on marketable securities	$ 12
Maximum [Member]
Unrealized gains on marketable securities		$ 1

RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)

12 Months Ended

Dec. 31, 2022

Research and Development [Abstract]

SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES

	2022		2021
	For the Years Ended December 31,
	2022		2021
Payroll and related expenses	$	3,558	$	3,030
Share-based compensation		387		183
Professional services		2,097		1,532
Materials		559		703
Patents		341		251
Rent		224		206
Office and maintenance expenses		100		123
Depreciation		102		72
Other		368		53
Research and development expense	$	7,736	$	6,153

CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)

12 Months Ended

Dec. 31, 2022

Cash and Cash Equivalents [Abstract]

SCHEDULE OF CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES

The following table sets forth our cash, cash equivalents and marketable securities as of December 31, 2022 and 2021:

	2022		2021
	As of December 31,
	2022		2021
Cash and cash equivalents:
Cash	$	1,195	$	13,493
U.S. treasury securities		1,247		-
Total cash and cash equivalents	$	2,442	$	13,493

Marketable securities:
Money market mutual funds	$	1,999	$	1,999
U.S. treasury securities		3,761		-
Total marketable securities	$	5,760	$	1,999

Total cash and cash equivalents and marketable securities	$	8,202	$	15,492

SUMMARY OF PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cost	$ 608	$ 533
Accumulated Depreciation	387	289
Net book value	221	244
Research Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Cost	71	68
Accumulated Depreciation	63	54
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	229	229
Accumulated Depreciation	135	89
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	308	236
Accumulated Depreciation	$ 189	$ 146

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES EXCLUDED FROM DILUTED LOSS PER SHARE (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Warrant to Underwriters 12.2019 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	138,307	175,889
Series A and B Warrants 10.2022 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	2,044,990
Warrant to Underwriters 10.2022 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	51,125
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	1,507,137	997,148
Series A and B Warrants 2013 and 2016 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from diluted loss per share	183	2,953

SCHEDULE OF STOCK OPTIONS OUTSTANDING (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2022 $ / shares
Equity [Abstract]
Exercise price	$ 0.01

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expenses And Other Current Assets
Amounts due from government institutions	$ 103	$ 174
Prepaid expenses	429	126
Total prepaid expenses and other current assets	$ 532	$ 300